CONMED (NYSE:CNMD) Q4 2025 Earnings call January 28, 2026 04:30 PM ET Company ParticipantsPatrick Beyer - President and CEOTodd Garner - EVP and CFOConference Call ParticipantsMatthew O'Brien - AnalystMike Matson - AnalystRobbie Marcus - AnalystTravis Steed - AnalystVik Chopra - AnalystYoung Li - AnalystOperatorGood day, and thank you for standing by. Welcome to CONMED's fourth quarter fiscal 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's present ...

Core Insights - IDEXX Laboratories, Inc. (IDXX) is scheduled to release its fourth-quarter 2025 results on February 2, before the market opens [1] - The company reported adjusted earnings per share (EPS) of $3.40 in the last quarter, exceeding the Zacks Consensus Estimate by 8.28%, and has consistently beaten estimates over the past four quarters with an average surprise of 7.12% [1] Q4 Estimates - The Zacks Consensus Estimate for fourth-quarter revenues is $1.07 billion, reflecting a 12.2% increase from the previous year [2] - The EPS estimate stands at $2.93, indicating an 11.8% rise year-over-year [2] - Earnings estimates have remained stable at $2.93 over the past 60 days [3] Key Drivers of Performance - The Companion Animal Group (CAG) is expected to maintain its momentum, driven by strong commercial execution and recurring revenues from diagnostics, particularly in the U.S. and international markets [4] - IDEXX VetLab consumables are anticipated to benefit from increased test volumes and higher realized prices [4] - Key innovations such as the IDEXX inVue Dx Analyzer and IDEXX Cancer Dx panel are likely to have seen strong adoption, contributing to increased recurring revenues in Veterinary Software and Services [5] Segment Performance - CAG revenues are projected to grow by 12.7% year-over-year in Q4 2025 [7] - The Water segment is expected to see revenues increase by 7.8% year-over-year, supported by higher prices and volumes [10] - The Livestock, Poultry and Dairy (LPD) division is also anticipated to experience a 7.8% year-over-year revenue increase, driven by higher test volumes and prices across various regions [11] Earnings Model Insights - IDEXX Laboratories has an Earnings ESP of 0.00%, indicating no expected surprise in earnings [12] - The company currently holds a Zacks Rank of 2 (Buy) [13]

Financial Data and Key Metrics Changes - In FY 2025, the company achieved record revenue of $21.8 billion, representing a growth of 7.7% adjusted for foreign exchange and 2.9% organic growth [4] - Adjusted gross margin increased by 140 basis points, contributing to an 80 basis points expansion in adjusted operating margin, resulting in a record 25% adjusted operating margin [5][7] - Adjusted diluted EPS grew by 9.6%, inclusive of tariffs, while the company returned $2.2 billion to shareholders, including a $1 billion share buyback [5] Business Line Data and Key Metrics Changes - New BD delivered organic revenue growth of 3.9%, with solid growth across key platforms [4] - The company launched over 125 new products and added $1.3 billion through more than 20 accretive high-growth tuck-in acquisitions [6] Market Data and Key Metrics Changes - The company navigated a dynamic market environment, including changes in research spending, vaccine utilization, tariffs, and ongoing geopolitical uncertainty [7] - The agreement to combine the Biosciences and Diagnostic Solutions business with Waters Corp is expected to create a life science and diagnostics leader, enhancing growth opportunities [8] Company Strategy and Development Direction - The company is transitioning to a new growth strategy called "Excellence Unleashed," focusing on three strategic priorities: compete, innovate, and deliver [9] - The capital allocation framework prioritizes share repurchases, reliable and increasing dividends, and focused tuck-in M&A in high-growth markets [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute on the new growth strategy and emphasized the importance of operational excellence for reinvestment in commercial and innovation capabilities [9][10] - The company aims to maximize its platforms for faster long-term growth, building on the advancements made over the last five years [10] Other Important Information - The company announced its 54th consecutive year of dividend increases, reflecting the consistency and reliability of its dividend policy [5] - The transaction with Waters Corp is expected to close on February 9, subject to customary closing conditions [8] Q&A Session Summary Question: Were there any questions from shareholders? - There were no questions received during the Q&A session [14]

"中国经济在面临复杂国内外环境时表现出增长韧性。"古巴拉丁美洲通讯社报道称，"十四五"时 期，中国经济总量先后突破110万亿元、120万亿元、130万亿元和140万亿元人民币大关，出口和战略性 新兴产业投资不断增加。报道援引分析人士观点称，"在全球贸易和全球金融面临挑战的当下，中国依 然是全球经济增长的重要引擎"。 俄罗斯卫星通讯社报道称，中国国内生产总值首次跨越140万亿元人民币大关，标注出中国经济发 展新刻度。中国坚定不移实施创新驱动发展战略，依靠发展壮大新质生产力促进经济高质量发展，生产 率持续提升，制造业技术含量不断提高。中国对世界经济增长、技术变革、全球治理的贡献愈发显著。 "在面临复杂国内外环境时表现出增长韧性" 规模以上工业增加值比上年增长5.9%，货物进出口总额比上年增长3.8%，最终消费支出对经济增 长贡献率超过五成，居民人均可支配收入实际增长5.0%，与经济增长同步……2025年，中国经济取得 一系列亮眼成绩。 "面对复杂严峻的国际形势，2025年中国经济预期目标圆满实现，得益于中国政府采取的一系列经 济提振措施。"巴基斯坦联合通讯社报道称，2025年，中国政府推出涵盖家电、汽车、智能手机 ...

PresentationGood morning, everyone, and welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Varun, and it is my pleasure to invite on stage today Nyxoah, represented by their CEO, Olivier Taelman. Please put your hands together for Olivier.Olivier TaelmanCEO & Executive Director Thank you. Let me start by thanking JPMorgan for the invitation. My name is Olivier Taelman. I am the CEO of Nyxoah. Nyxoah, a medtech company offering an innovative solution by neurostimulation to help patients su ...

Core Insights - The successful implementation of non-invasive brain-computer interface (BCI) technology at the First Affiliated Hospital of Bengbu Medical College has provided new rehabilitation hope for acute stroke patients with hemiplegia [2][3] - This innovative treatment allows for early neural repair interventions within 72 hours of stroke onset, addressing the limitations of traditional thrombolysis and thrombectomy methods [2][3] Group 1: Treatment Details - The first patient treated was relatively young and exhibited left-sided hemiplegia, with noticeable instability despite being able to walk and raise their hand [2] - The treatment involved a non-invasive BCI approach, which was applied alongside conventional medication, leading to significant improvements in the patient's motor functions [3] - The BCI technology utilized high-precision MRI to create a personalized brain model, allowing for accurate targeting of the damaged areas [3] Group 2: BCI Technology Overview - BCI technology establishes a new communication channel between the brain and external devices, enabling direct interaction and control [4] - It can be categorized into invasive, semi-invasive, and non-invasive types, with non-invasive BCI being favored for its safety and broad applicability [5] Group 3: Market Potential and Future Applications - There is a large population of patients in China suffering from severe neurological disorders, including over 28 million stroke patients, which highlights the potential market for BCI technology [5] - The ongoing advancements in neuroscience, materials science, microelectronics, and artificial intelligence are expected to enhance the application prospects of BCI technology in various medical fields [5] - The non-invasive BCI approach is seen as a safer and more accessible option, likely to integrate into everyday life for a broader audience [6] Group 4: Clinical Development - The hospital is initiating treatment for a second batch of acute stroke patients and is actively exploring BCI applications in other neurological diseases such as Alzheimer's and Parkinson's [6]

Outset Medical (NasdaqGS:OM) FY Conference January 14, 2026 07:30 PM ET Company ParticipantsLeslie Trigg - Chair and CEORenee Gaeta - CFODenise Liu - Healthcare Investment Banking AssociateConference Call ParticipantsNone - Analyst 3None - Analyst 1None - Analyst 2Denise LiuHi everyone, my name is Denise Liu. I am an Associate here in Healthcare Investment Banking at JPMorgan. We're excited to be continuing the annual healthcare conference today with Leslie Trigg, Chair and CEO of Outset Medical. We'll have ...

Masimo FY Conference Summary Company Overview - **Company**: Masimo (NasdaqGS:MASI) - **Industry**: Patient Monitoring Technology - **Global Reach**: Serves over 200 million patients annually in over 150 countries [2][3] - **Revenue**: Over $1.5 billion with a strong installed base of 2.6 million units [3] - **Employee Retention**: High retention rate for engineers, with over 350 engineers [3] Financial Performance - **Q4 Growth**: Achieved over 9% growth for the year and over 11% for the quarter [3] - **Margin Expansion**: Expanded operating margin by 500 basis points and achieved over 30% EPS growth [4] - **Long-term Guidance**: Anticipates 7-10% growth over the next three years, aiming for a 30% operating margin and approaching $8 EPS by 2028 [4] Growth Strategy - **Masimo Growth Algorithm**: Focused on four key components driving growth: 1. U.S. Pulse Ox growth (40% of growth) 2. International growth (20%) 3. Advanced monitoring (one-third of growth) 4. New product introductions [6] - **Market Share**: Holds approximately 55% market share in the U.S. Pulse Ox market, growing at twice the market rate [7] - **Continuous Monitoring Opportunity**: Identified a $2 billion total addressable market for continuous monitoring of patients [9] Product Innovation - **Wearable Technology**: Launching Radius VSM, a first-generation wearable technology for continuous monitoring [18] - **Next-Gen Monitors**: New high and low acuity monitors expected by the end of 2027, with advanced features and AI algorithms [20] - **AI Integration**: Developing algorithms for opioid-induced respiratory depression and atrial fibrillation detection, enhancing patient care [22][24] Partnerships and Collaborations - **Strategic Partnerships**: Expanded agreements with Philips and GE Healthcare to enhance product offerings and market reach [16] - **Focus on Japan and Asia-Pacific**: Appointed a leader to grow business in these regions, which represent significant growth potential [15] Market Dynamics - **Untapped Market**: Continuous monitoring in low acuity settings is currently underutilized, presenting a growth opportunity as hospitals shift towards preventive care [34][36] - **Telehealth Solutions**: Enabling hospitals to provide telehealth services rather than direct-to-consumer sales, focusing on technology that supports hospital systems [53] Key Takeaways - **Momentum for 2026**: Strong performance in 2025 sets a solid foundation for growth in 2026, with a focus on innovation and market expansion [45][49] - **Patient-Centric Approach**: Emphasis on improving patient care through continuous monitoring and advanced technology solutions [29][36] This summary encapsulates the key points from the Masimo FY Conference, highlighting the company's strategic direction, financial performance, and innovative product pipeline.

Group 1 - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It mentions that users with ad-blockers may face restrictions when trying to access the content [1]

Summary of Fresenius SE Conference Call Company Overview - Fresenius SE is a comprehensive healthcare company with a diverse portfolio including hospitals, pharmaceuticals, medical technology, and innovative products and services [2][3] Key Industry Trends - **Longevity Trend**: Increasing aging population and rising chronic diseases leading to workforce challenges [3][4] - **Healthcare System Inefficiencies**: Most systems, especially in Western countries, are inefficient, creating opportunities for Fresenius to address these challenges [4] - **Generics Market**: 90% of prescribed drugs in the U.S. are generics, accounting for only about 10% of costs, positioning Fresenius as a solution provider in drug shortages [5] Business Segments Fresenius Kabi - **IV Generics and Fluids**: Strong market position with stable growth (2%-3%) and high margins (22%) [7][8] - **Nutrition**: Significant growth (46% market growth) with a projected $2.5 billion business growing at 4%-6% [9] - **Biopharma**: Expected to reach nearly $1 billion in sales by 2026, with a target to double revenues by 2030 [10][11] Hospital Business - Largest hospital chains in Germany (Helios) and Spain (Quirónsalud) with a focus on quality and efficiency [12][13] - High margins and stable earnings, with ongoing structural changes to increase efficiency [13] Financial Performance - **Growth Metrics**: 6% growth in Q1 to Q3, with EPS growth of 14% [14] - **Debt Management**: Improved net debt to EBITDA ratio from nearly 4 to 3.0, allowing for capital deployment [14][24] - **Capital Allocation**: Focus on R&D, CapEx, and potential bolt-on M&As to scale operations [21][24] Strategic Focus - **Rejuvenation Phase**: Emphasis on innovation and execution to drive incremental revenue and margin expansion [20] - **Management Incentives**: New share ownership guidelines for leadership to align interests with shareholders [17] Market Dynamics - **U.S. Market**: Fresenius covers 70% of the FDA Essential Medicines List, playing a vital role in addressing drug shortages [28][29] - **China Market**: Challenges due to Value-Based Procurement (VBP) but potential for growth with new factory openings [35] MedTech and Innovation - **Growth in MedTech**: Expected growth of 8%-10% driven by innovative products like the Ivenix pump and software solutions [36][37] - **Biosimilars**: Focus on expanding market presence and leveraging regulatory changes to enhance competitiveness [40][41] Challenges and Outlook - **Regulatory Environment**: Anticipated changes may reduce costs and time to market but also increase competition [44] - **Helios Germany**: Facing headwinds in 2025 but potential tailwinds in 2026 with industry surcharges [46] Conclusion - Fresenius SE is well-positioned to capitalize on healthcare trends and inefficiencies, with a strong focus on innovation, operational efficiency, and strategic capital deployment to drive future growth [22][27]